Table 6. The prognostic value of PRDX5 mRNA expression in ovarian cancer.
| Overall survival | Progress-free survival | |||||
|---|---|---|---|---|---|---|
| Cases | HR (95% CI) | P-value | Cases | HR (95% CI) | P-value | |
| Histology | ||||||
| All cancer patients | 655 | 1.22 (0.99–1.49) | 0.062 | 614 | 1.28 (1.05–1.56) | 0.013* |
| Serous cancer patients | 523 | 1.25 (1–1.57) | 0.046* | 483 | 0.8 (0.64–1.01) | 0.057 |
| Endometrioid cancer patients | 30 | 7.8 (0.81–75.29) | 0.036* | 44 | 6.85 (1.52–30.91) | 0.0039* |
| Pathological grades | ||||||
| I | 41 | 0.26 (0.07–0.97) | 0.031* | 28 | 0.45 (0.11–1.8) | 0.25 |
| II | 162 | 1.66 (1.07–2.56) | 0.022* | 161 | 1.54 (1.06–2.23) | 0.022* |
| III | 392 | 1.45 (1.11–1.89) | 0.0067* | 315 | 0.84 (0.64–1.1) | 0.2 |
| Clinical stages | ||||||
| I and II | 83 | 0.33 (0.12–0.93) | 0.027* | 115 | 0.54 (0.25–1.16) | 0.11 |
| III and IV | 487 | 1.23 (0.98–1.54) | 0.076 | 494 | 1.4 (1.14–1.73) | 0.0011* |
| Chemotherapy | ||||||
| Contains Platin | 1409 | 1.37 (1.09–1.73) | 0.0074* | 1259 | 1.41 (1.15–1.73) | 0.00079* |
| Contains Taxol | 793 | 1.44 (1.08–1.92) | 0.012* | 715 | 1.44 (1.13–1.84) | 0.0033* |
| Contains Taxol+Platin | 776 | 1.44 (1.08–1.91) | 0.013* | 698 | 1.45 (1.13–1.85) | 0.003* |
*P<0.05.